Evidence map›Paper›PMID 23349960›Full record

ArticlePloS one2013

Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats.

Raed N Bou Matar, Janet D Klein, Jeff M Sands

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Raed N Bou MatarDepartment of Pediatric Medicine, Emory University, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Janet D Klein
Jeff M Sands
Emory University · USChildren's Healthcare of Atlanta · US

Funding

Regulation of Renal Inner Medullary FunctionR01DK041707 · NIDDK · EMORY UNIVERSITY · PI SANDS, JEFF M · 1996 to 2017
$4.3M
Regulation of Urea Transport by PKC-alphaR01DK089828 · NIDDK · EMORY UNIVERSITY · PI SANDS, JEFF M · 2011 to 2014
$1.5M
Novel Mouse Models for the Study of Urea TransportersR21DK091147 · NIDDK · EMORY UNIVERSITY · PI SANDS, JEFF M · 2011 to 2012
$233k
NIDDK NIH HHS R01 DK041707NIDDK NIH HHS R01 DK089828NIDDK NIH HHS R01-DK41707NIDDK NIH HHS R01-DK89828NIDDK NIH HHS R21 DK091147NIDDK NIH HHS R21-DK91147
6 · The paper itself

Abstract

Nephrotic syndrome is associated with up-regulation of the heparin-binding epidermal growth factor (HB-EGF). Erlotinib blocks the activation of the epidermal growth factor receptor (EGFR) in response to HB-EGF. This study investigates the effect of Erlotinib on the progression of proteinuria, renal dysfunction, and salt retention in doxorubicin treated nephrotic rats. Male rats were divided into 3 pair-fed groups (n = 13/group) as follows: Control rats (Ctrl); rats receiving intravenous doxorubicin (Dox); and rats receiving intravenous doxorubicin followed by daily oral Erlotinib (Dox + Erl). Upon establishment of high grade proteinuria, urine sodium and creatinine clearance were measured. Kidney tissue was dissected and analyzed for γ-epithelial sodium channel (γENaC), sodium-potassium -chloride co-transporter 2 (NKCC2), sodium chloride co-transporter (NCC), aquaporin 2 (AQP2), and EGFR abundances using western blot. Creatinine clearance was preserved in the Dox + Erl rats as compared to the Dox group (in ml/min: Ctrl: 5.2±.5, Dox: 1.9±0.3, Dox + Erl: 3.6±0.5). Despite a minimal effect on the degree of proteinuria, Erlotinib prevented salt retention (Urinary Na in mEq/d: Ctrl: 2.2±0.2, Dox: 1.8±0.3, Dox + Erl: 2.2±0.2). The cleaved/uncleaved γENaC ratio was increased by 41±16% in the Dox group but unchanged in the Dox + Erl group when compared to Ctrl. The phosphorylated EGFR/total EGFR ratio was reduced by 74±7% in the Dox group and by 77±4% in the Dox + Erl group. In conclusion, Erlotinib preserved renal function and prevented salt retention in nephrotic rats. The observed effects do not appear to be mediated by direct blockade of EGFR.

Indexed as

AnimalsAntibiotics, AntineoplasticAquaporin 2CreatinineDoxorubicinEpithelial Sodium ChannelsErbB ReceptorsErlotinib HydrochlorideHeparin-binding EGF-like Growth FactorHumansIntercellular Signaling Peptides and ProteinsMaleNephrotic SyndromeProtein Kinase InhibitorsProteinuriaQuinazolinesAntibiotics, AntineoplasticAquaporin 2CreatinineDoxorubicinEgfr protein, ratEpithelial Sodium ChannelsErbB ReceptorsErlotinib HydrochlorideHBEGF protein, humanHbegf protein, ratHeparin-binding EGF-like Growth FactorIntercellular Signaling Peptides and ProteinsProtein Kinase InhibitorsQuinazolinesSLC12A1 protein, humanSlc12a1 protein, ratSodium Chloride SymportersSodium-Potassium-Chloride SymportersSolute Carrier Family 12, Member 1

Identifiers

PMID23349960
PMCPMC3548782
OpenAlexW2171395506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.